Hyper-glycosylated antibodies with selective Fc receptor binding
Means for improving the effector functions of current immunotherapeutic antibodies through targeted hyper-glycosylation of the antibody Fc region are disclosed, as well as antibody variants having hyper-glycosylated Fc regions. Fc receptor-mediated effector functions have been shown to be a critical contributor to the efficacies of numerous therapeutic antibodies currently in clinical use. Targeted hyper-glycosylation of antibodies has the potential to significantly improve current immunotherapies for cancer.
1. An antibody comprising a human IgG Fc region wherein one or more triplets of three contiguous amino acids on one or both chains of the Fc region is replaced by an Asn-X-Thr/Ser triplet, wherein the triplets are independently located such that the Asn of the triplet is at one or more of positions 226 and 290 , wherein the positions correspond to the amino acid sequence of human IgG1 heavy chain using Eu numbering system, wherein each X is any amino acid except proline, and wherein the Asn of the triplet is glycosylated, partially glycosylated or unglycosylated.
2. The antibody according to claim 1 , wherein the Fc region is altered to comprise two Asn-X-Thr/Ser triplets located in the same positions on both chains of the Fc region, wherein one of the triplets is located such that the Asn of the triplet is at position 226 and wherein the other triplet is located such that the Asn of the triplet is at position 290 .
3. The antibody of claim 1 , wherein one or both chains of the Fc region have Asn-X-Thr/Ser triplet replacements at positions 226 - 228 .
4. The antibody of claim 3 , wherein both chains of the Fc region have the noted Asn-X-Thr/Ser triplets.
5. The antibody of claim 3 , wherein the antibody further comprises one or more additional amino acid replacements selected from the group consisting of S 298 A, E 333 A, and K 334 A, each independently on one or both chains of the Fc region.
6. The antibody of claim 3 , wherein the antibody further comprises one or more additional amino acid replacements selected from the group consisting of S 239 D, I 332 E, and A 330 L, each independently on one or both chains of the Fc region.
7. The antibody of claim 3 , wherein the antibody further comprises a G 236 A amino acid replacement on one or both chains of the Fc region.
8. The antibody of claim 3 , wherein the Asn-X-Thr/Ser triplets are Asn-Ser-Thr.
9. The antibody of claim 3 , wherein the Asn of the triplet is glycosylated.
10. The antibody of claim 3 , wherein the triplet is Asn-Ser-Thr.
11. The antibody of claim 10 , wherein the antibody further comprises one or more additional amino acid replacements selected from the group consisting of S 298 A, E 333 A, and K 334 A, each independently on one or both chains of the Fc region.
12. The antibody of claim 10 , wherein the antibody further comprises one or more additional amino acid replacements selected from the group consisting of S 239 D, I 332 E, and A 330 L, each independently on one or both chains of the Fc region.
13. The antibody of claim 10 , wherein the antibody further comprises a G 236 A amino acid replacement on one or both of the chains of the Fc region.
14. The antibody of claim 10 , wherein both chains of the Fc region have the Asn-Ser-Thr replacements.
15. The antibody of claim 10 , wherein the Asn of the triplet is glycosylated.
16. The antibody of claim 10 , wherein both chains of the Fc region have Asn-Ser-Thr replacements at positions 226 - 228 , both chains of the Fc region have Asn-Ser-Thr replacements at positions 290 - 292 , wherein Asn residues present at positions 226 and 290 are glycosylated, and wherein both heavy chains have a S 298 A amino acid replacement corresponding to the amino acid sequence of human IgG1.